局部前列腺癌立体定向体放射治疗后的前列腺特异性抗原动力学:范围综述和荟萃分析。

IF 4.9 1区 医学 Q1 ONCOLOGY Radiotherapy and Oncology Pub Date : 2024-11-16 DOI:10.1016/j.radonc.2024.110642
Cas Stefaan Dejonckheere , Lara Caglayan , Andrea Renate Glasmacher , Shari Wiegreffe , Julian Philipp Layer , Younèss Nour , Davide Scafa , Gustavo Renato Sarria , Simon Spohn , Markus Essler , Stefan Hauser , Manuel Ritter , Marit Bernhardt , Glen Kristiansen , Anca-Ligia Grosu , Constantinos Zamboglou , Eleni Gkika
{"title":"局部前列腺癌立体定向体放射治疗后的前列腺特异性抗原动力学:范围综述和荟萃分析。","authors":"Cas Stefaan Dejonckheere ,&nbsp;Lara Caglayan ,&nbsp;Andrea Renate Glasmacher ,&nbsp;Shari Wiegreffe ,&nbsp;Julian Philipp Layer ,&nbsp;Younèss Nour ,&nbsp;Davide Scafa ,&nbsp;Gustavo Renato Sarria ,&nbsp;Simon Spohn ,&nbsp;Markus Essler ,&nbsp;Stefan Hauser ,&nbsp;Manuel Ritter ,&nbsp;Marit Bernhardt ,&nbsp;Glen Kristiansen ,&nbsp;Anca-Ligia Grosu ,&nbsp;Constantinos Zamboglou ,&nbsp;Eleni Gkika","doi":"10.1016/j.radonc.2024.110642","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Stereotactic body radiotherapy (SBRT) is emerging as a valuable treatment modality for localized prostate cancer, with promising biochemical progression-free survival rates. Longitudinal assessment of prostate-specific antigen (PSA) is the mainstay of follow-up after treatment. PSA kinetics and dynamics are well-established in the context of brachytherapy and conventionally fractionated radiotherapy, yet little is known in the context of prostate SBRT.</div></div><div><h3>Methods</h3><div>A review of available literature in MEDLINE, Scopus, and Embase was performed, focusing on studies reporting PSA slope, nadir, bounce, and biochemical failure after prostate SBRT.</div></div><div><h3>Results</h3><div>Thirty-three records (45 % prospective) encompassing 9949 patients were included. SBRT dose ranged from 32–50 Gy in 4–5 fractions and overall median follow-up time (range) was 41 (15–74) months. Use of androgen deprivation therapy ranged from 0–38 %. SBRT was characterized by a steep initial decline of PSA, slowing down over time and ultimately yielding a lower nadir in comparison with conventional radiotherapy, with a median value (range) of 0.24 (0.1–0.6) ng/mL after a median time (range) of 33.1 (6–54) months. There was an inverse correlation between the highest SBRT dose in a trial and PSA nadir (<em>r</em> = − 0.59; <em>p</em> &lt; 0.001). Benign PSA bounce occurred in 30 % of patients across all studies, after a median time (range) of 14.8 (9–36) months and with a median size (range) of 0.5 (0.3–1.1) ng/mL. There was no significant correlation between bounce and dose, nadir nor biochemical failure. There was, however, a significant inverse correlation between ADT use and PSA bounce frequency (<em>r</em> = −0.49; <em>p</em> = 0.046).</div></div><div><h3>Conclusion</h3><div>PSA kinetics and dynamics after SBRT for localized prostate cancer are different from those in other established radiotherapy modalities. Benign PSA bounce is very common. Clinicians should be aware of these factors and patients should be counseled accordingly, preventing unnecessary distress or salvage treatment.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"202 ","pages":"Article 110642"},"PeriodicalIF":4.9000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis\",\"authors\":\"Cas Stefaan Dejonckheere ,&nbsp;Lara Caglayan ,&nbsp;Andrea Renate Glasmacher ,&nbsp;Shari Wiegreffe ,&nbsp;Julian Philipp Layer ,&nbsp;Younèss Nour ,&nbsp;Davide Scafa ,&nbsp;Gustavo Renato Sarria ,&nbsp;Simon Spohn ,&nbsp;Markus Essler ,&nbsp;Stefan Hauser ,&nbsp;Manuel Ritter ,&nbsp;Marit Bernhardt ,&nbsp;Glen Kristiansen ,&nbsp;Anca-Ligia Grosu ,&nbsp;Constantinos Zamboglou ,&nbsp;Eleni Gkika\",\"doi\":\"10.1016/j.radonc.2024.110642\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Stereotactic body radiotherapy (SBRT) is emerging as a valuable treatment modality for localized prostate cancer, with promising biochemical progression-free survival rates. Longitudinal assessment of prostate-specific antigen (PSA) is the mainstay of follow-up after treatment. PSA kinetics and dynamics are well-established in the context of brachytherapy and conventionally fractionated radiotherapy, yet little is known in the context of prostate SBRT.</div></div><div><h3>Methods</h3><div>A review of available literature in MEDLINE, Scopus, and Embase was performed, focusing on studies reporting PSA slope, nadir, bounce, and biochemical failure after prostate SBRT.</div></div><div><h3>Results</h3><div>Thirty-three records (45 % prospective) encompassing 9949 patients were included. SBRT dose ranged from 32–50 Gy in 4–5 fractions and overall median follow-up time (range) was 41 (15–74) months. Use of androgen deprivation therapy ranged from 0–38 %. SBRT was characterized by a steep initial decline of PSA, slowing down over time and ultimately yielding a lower nadir in comparison with conventional radiotherapy, with a median value (range) of 0.24 (0.1–0.6) ng/mL after a median time (range) of 33.1 (6–54) months. There was an inverse correlation between the highest SBRT dose in a trial and PSA nadir (<em>r</em> = − 0.59; <em>p</em> &lt; 0.001). Benign PSA bounce occurred in 30 % of patients across all studies, after a median time (range) of 14.8 (9–36) months and with a median size (range) of 0.5 (0.3–1.1) ng/mL. There was no significant correlation between bounce and dose, nadir nor biochemical failure. There was, however, a significant inverse correlation between ADT use and PSA bounce frequency (<em>r</em> = −0.49; <em>p</em> = 0.046).</div></div><div><h3>Conclusion</h3><div>PSA kinetics and dynamics after SBRT for localized prostate cancer are different from those in other established radiotherapy modalities. Benign PSA bounce is very common. Clinicians should be aware of these factors and patients should be counseled accordingly, preventing unnecessary distress or salvage treatment.</div></div>\",\"PeriodicalId\":21041,\"journal\":{\"name\":\"Radiotherapy and Oncology\",\"volume\":\"202 \",\"pages\":\"Article 110642\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiotherapy and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0167814024043044\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiotherapy and Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167814024043044","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:立体定向体放射治疗(SBRT)正在成为一种治疗局部前列腺癌的重要方法,其无生化进展生存率很高。前列腺特异性抗原(PSA)的纵向评估是治疗后随访的主要方法。近距离放射治疗和传统分次放射治疗中的 PSA 动力学和动态已得到充分证实,但前列腺 SBRT 的相关研究却知之甚少:方法:对MEDLINE、Scopus和Embase中的现有文献进行了回顾,重点关注报告前列腺SBRT后PSA的斜率、最低点、反弹和生化失败的研究:结果:共纳入33项研究(45%为前瞻性研究),涵盖9949名患者。SBRT剂量为32-50 Gy,分4-5次进行,总体中位随访时间(范围)为41(15-74)个月。使用雄激素剥夺疗法的比例为 0-38%。与传统放疗相比,SBRT的特点是PSA最初急剧下降,随着时间的推移逐渐放缓,最终达到较低的低点,中位值(范围)为0.24(0.1-0.6)纳克/毫升,中位时间(范围)为33.1(6-54)个月。在一项试验中,SBRT 的最高剂量与 PSA 最低值呈反向相关(r = - 0.59;p 结论:PSA 的动力学和动态变化与 SBRT 的最高剂量呈反向相关:局部前列腺癌 SBRT 治疗后的 PSA 动力学和动态变化与其他成熟的放疗方式不同。良性 PSA 反弹非常常见。临床医生应了解这些因素,并对患者进行相应的指导,以避免不必要的痛苦或挽救治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis

Purpose

Stereotactic body radiotherapy (SBRT) is emerging as a valuable treatment modality for localized prostate cancer, with promising biochemical progression-free survival rates. Longitudinal assessment of prostate-specific antigen (PSA) is the mainstay of follow-up after treatment. PSA kinetics and dynamics are well-established in the context of brachytherapy and conventionally fractionated radiotherapy, yet little is known in the context of prostate SBRT.

Methods

A review of available literature in MEDLINE, Scopus, and Embase was performed, focusing on studies reporting PSA slope, nadir, bounce, and biochemical failure after prostate SBRT.

Results

Thirty-three records (45 % prospective) encompassing 9949 patients were included. SBRT dose ranged from 32–50 Gy in 4–5 fractions and overall median follow-up time (range) was 41 (15–74) months. Use of androgen deprivation therapy ranged from 0–38 %. SBRT was characterized by a steep initial decline of PSA, slowing down over time and ultimately yielding a lower nadir in comparison with conventional radiotherapy, with a median value (range) of 0.24 (0.1–0.6) ng/mL after a median time (range) of 33.1 (6–54) months. There was an inverse correlation between the highest SBRT dose in a trial and PSA nadir (r = − 0.59; p < 0.001). Benign PSA bounce occurred in 30 % of patients across all studies, after a median time (range) of 14.8 (9–36) months and with a median size (range) of 0.5 (0.3–1.1) ng/mL. There was no significant correlation between bounce and dose, nadir nor biochemical failure. There was, however, a significant inverse correlation between ADT use and PSA bounce frequency (r = −0.49; p = 0.046).

Conclusion

PSA kinetics and dynamics after SBRT for localized prostate cancer are different from those in other established radiotherapy modalities. Benign PSA bounce is very common. Clinicians should be aware of these factors and patients should be counseled accordingly, preventing unnecessary distress or salvage treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Radiotherapy and Oncology
Radiotherapy and Oncology 医学-核医学
CiteScore
10.30
自引率
10.50%
发文量
2445
审稿时长
45 days
期刊介绍: Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.
期刊最新文献
A critical reflection of radiotherapy on osseous free flaps in mandibular segmental resection and immediate reconstruction in locally advanced oral squamous cell carcinoma: A cohort study Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: A long-term, multicenter cohort study. Prevalence of depressive and anxiety symptoms in patients with head and neck cancer undergoing radiotherapy: A systematic review and meta-analysis of longitudinal studies. Contents International collaboration of neoadjuvant stereotactic radiosurgery for brain metastases: The INTERNEO individual patient data pooled analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1